

Supplementary Table I. Associations of cytokines, resilience and severity of symptoms with treatment.

Variable	Immunosuppressors (n=30)	DMARDs (n=30)	Corticoids (n=30)	Antimalarials (n=30)	All ^a (n=30)
IL-1 β	0.4373	0.0109*	0.3606	0.0765	0.0560
IL-2	0.5702	0.4566	0.2454	0.3464	0.5911
IL-4	1.0000	0.0016*	0.1326	0.0765	0.0500
IL-5	0.5001	0.1733	0.2665	0.1664	0.3033
IL-6	0.2266	0.6796	0.9388	0.3683	0.8946
IL-8	0.0240*	0.2020	0.0329*	0.4867	0.4212
IL-9	0.1102	0.0903	0.7340	0.2840	0.2406
IL-10	0.0505	0.2634	0.7656	0.1664	0.0921
IL-12/IL-23p40	0.3930	0.5823	0.2594	0.1641	0.5820
IL-13	0.5307	0.0256*	0.2987	0.1528	0.0867
IL17A	0.5135	0.0070*	0.2209	0.1235	0.0326*
TNF- α	0.5735	0.0080*	0.2416	0.1094	0.0409*
G-CSF	0.1388	0.0778	0.5520	0.0734	0.0856
IFN- α	0.6019	0.0097*	0.1649	0.0793	0.0636
IFN- γ	0.0046*	0.2944	0.6612	0.3362	0.6317
SSPRO	0.0767	0.7413	0.9609	0.3162	0.3969
BRS	0.5403	0.8771	0.7304	0.1052	0.6101

Analyses were done using Mann-Whitney U-test to find associations between treatment and cytokines levels, SSPRO results and BRS. ^aThis variable includes any combination of treatment with immunosuppressors, DMARDs, corticoids or antimalarials, ^{*}Statistical significant. DMARDs: disease-modifying anti-rheumatic drugs; SSPRO: scleroderma skin patient report outcome questionnaire; BRS: brief resilience scale.

Supplementary Table II. Autoantibodies in patients with SSc.

Antibody	Frequency (%) ^b	BRS ^a	SSPRO ^a
Nucleosomes	0 (0.00)	-	-
Histones	0 (0.00)	-	-
dsDNA	1 (2.90)	-	-
Ro60	9 (25.70)	0.8497	0.1043
Ro52	8 (22.90)	0.3241	0.5956
SSB/La	5 (14.30)	0.3685	0.4090
U1 RNP	5 (14.30)	0.1423	0.2778
smD1	2 (5.70)	-	-
PCNA	0 (0.00)	-	-
P0	1 (2.90)	-	-
ACA _p B	22 (62.90)	0.0898	0.7455
Sc170	1 (2.90)	-	-
AMA M2	7 (20.00)	0.6637	0.6059
Jo-1	0 (0.00)	-	-
PM-Scl	1 (2.90)	-	-
Mi-2	2 (5.70)	-	-
Ku	1 (2.90)	-	-

^aAnalyses were done using Mann-Whitney U-test to find associations between autoantibodies, SSPRO and BRS scores. ^bOnly those autoantibodies with more than 4 positive results were included in statistical analysis. SSPRO: scleroderma skin patient report outcome questionnaire; BRS: brief resilience scale; dsDNA: double-stranded DNA; U1 RNP: U1 ribonucleoprotein; PCNA: proliferating cell nuclear antigen; ACA_pB: anticentromere antibodies portion B; AMA M2: anti-mitochondrial antibodies portion M2.